A Phase 1 interventional study of DC-806 and Midazolam in Healthy Participants, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this study is to assess the effect of DC-806 on the pharmacokinetics (PK) of cytochrome 3A4 (CYP3A4) substrate, midazolam and its active metabolite, 1-hydroxymidazolam, cytochrome 2C8 (CYP2C8) substrate repaglinide, P-glycoprotein (P-gp) transporter substrate digoxin, and breast cancer resistant protein (BCRP)/ organic anion transporter protein-1B1 (OATP1B1) transporter substrate rosuvastatin in healthy participants.
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.
First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Participants were administered a single oral dose of the 2-probe CYP substrate cocktail consisting of 2 milligram (mg) midazolam and 0.5 mg repaglinide under fasted conditions in the morning on Day 1. * From Days 4 through 8, participants received oral doses of 800 mg DC-806 twice daily. A single oral dose of 2-probe CYP substrate cocktail consisting of 2 mg midazolam and 0.5 mg repaglinide was co-administered under fasted conditions 1.5 hours after DC-806 dosing in the morning of Day 7.
Drug: DC-806 · Drug: Midazolam · Drug: Repaglinide
* Participants were administered a single oral dose of the 2-probe transporter substrate cocktail consisting of 0.25 mg digoxin and 5 mg rosuvastatin under fasted conditions in the morning on Day 1. * From Days 5 through 9, participants received oral doses of 800 mg of DC-806 twice daily. A single oral dose of the 2-probe transporter substrate cocktail consisting of 0.25 mg digoxin and 5 mg rosuvastatin was co-administered under fasted conditions 1.5 hours after DC-806 dosing in the morning of Day 8.
Drug: DC-806 · Drug: Digoxin · Drug: Rosuvastatin
Oral tablets
Oral syrup
Oral tablets
Oral tablets
Oral tablets
Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Midazolam
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Cohort 1: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t, Where t is the Last Point With Concentrations Above the Lower Limit of Quantification (AUC0-t) of Midazolam
Cohort 1: AUC0-t of Midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Cohort 1: AUC From Time 0 to Infinity (AUC0-inf) of Midazolam
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Cohort 1: Cmax of 1-hydroxymidazolam
Cohort 1: Cmax of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Cohort 1: AUC0-t of 1-hydroxymidazolam
Cohort 1: AUC0-t of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Cohort 1: AUC0-inf of 1-hydroxymidazolam
Cohort 1: AUC0-inf of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 hours postdose on Days 1 and 7
Cohort 1: Cmax of Repaglinide
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
Cohort 1: AUC0-t of Repaglinide
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
Cohort 1: AUC0-inf of Repaglinide
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours postdose on Days 1 and 7
Cohort 2: Cmax of Digoxin
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Cohort 2: AUC0-t of Digoxin
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Cohort 2: AUC0-inf of Digoxin
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Cohort 2: Cmax of Rosuvastatin
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Cohort 2: AUC0-t of Rosuvastatin
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Cohort 2: AUC0-inf of Rosuvastatin
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
Time frame: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96 hours postdose on Days 1 and 8
Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.
Time frame: Cohort 1: Day 1 up to Day 16; Cohort 2: Day 1 up to Day 22
| Milestone | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) |
|---|---|---|
| Started | 14 | 14 |
| Safety analysis set | 14 | 14 |
| Completed | 14 | 12 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 2 |
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
| nanograms per milliliter (ng/mL) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) |
|---|---|
| Day 1 | 8.27 ± 27.9 |
| Day 7 | 24.9 ± 29.4 |
Cohort 1: AUC0-t of Midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) |
|---|---|
| Day 1 | 18.4 ± 27.4 |
| Day 7 | 82.6 ± 36.9 |
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) |
|---|---|
| Day 1 | 21.4 ± 24.5 |
| Day 7 | 97.1 ± 35.8 |
Cohort 1: Cmax of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
| nanograms per milliliter (ng/mL) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) |
|---|---|
| Day 1 | 2.94 ± 64.5 |
| Day 7 | 2.95 ± 37.9 |
Cohort 1: AUC0-t of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) |
|---|---|
| Day 1 | 5.05 ± 106.6 |
| Day 7 | 7.69 ± 102.3 |
Cohort 1: AUC0-inf of 1-hydroxymidazolam, an active metabolite of midazolam. The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) |
|---|---|
| Day 1 | 13.2 ± 100.7 |
| Day 7 | 11.7 ± 5.4 |
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
| nanograms per milliliter (ng/mL) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) |
|---|---|
| Day 1 | 7.68 ± 50.2 |
| Day 7 | 14.4 ± 38.8 |
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) |
|---|---|
| Day 1 | 13.3 ± 62.4 |
| Day 7 | 28 ± 48.3 |
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe CYP substrate cocktail.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) |
|---|---|
| Day 1 | 14.7 ± 69.7 |
| Day 7 | 23.8 ± 34.5 |
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
| nanograms per milliliter (ng/mL) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) |
|---|---|
| Day 1 | 0.948 ± 25.0 |
| Day 8 | 1.39 ± 23.7 |
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) |
|---|---|
| Day 1 | 14.2 ± 24.2 |
| Day 8 | 15.4 ± 28.5 |
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) |
|---|---|
| Day 1 | 14.6 |
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
| nanograms per milliliter (ng/mL) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) |
|---|---|
| Day 1 | 2.85 ± 60 |
| Day 8 | 2.62 ± 85.3 |
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) |
|---|---|
| Day 1 | 29.7 ± 64.5 |
| Day 8 | 25.4 ± 56.8 |
The timepoints mentioned in the timeframe were relative to the administration of the 2-probe transporter substrate cocktail.
| hour*nanograms per milliliter (h*ng/mL) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) |
|---|---|
| Day 1 | 26.7 ± 47.8 |
| Day 8 | 23.1 ± 35.8 |
A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.
| Participants | Cohort 1: Midazolam + Repaglinide (Days 1 to 3) | Cohort 1: DC-806 (Days 4 to 6) | Cohort 1: DC-806 + Midazolam + Repaglinide (From Day 7) | Cohort 1: Overall [(DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)] | Cohort 2: Digoxin + Rosuvastatin (Days 1 to 4) | Cohort 2: DC-806 (Days 5 to 7) | Cohort 2: DC-806 + Digoxin + Rosuvastatin (From Day 8) | Cohort 2: Overall [(DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)] |
|---|---|---|---|---|---|---|---|---|
| Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 0 | 2 | 2 | 2 | 2 | 2 | 1 | 5 |
Collected over Cohort 1: Day 1 up to Day 16; Cohort 2: Day 1 up to Day 22.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Midazolam + Repaglinide (Days 1 to 3) | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| Cohort 1: DC-806 (Days 4 to 6) | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Cohort 1: DC-806 + Midazolam + Repaglinide (From Day 7) | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Cohort 1: Overall [(DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)] | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Cohort 2: Digoxin + Rosuvastatin (Days 1 to 4) | 0/14 (0%) | 0/14 (0%) | 2/14 (14.3%) |
| Cohort 2: DC-806 (Days 5 to 7) | 0/13 (0%) | 0/13 (0%) | 2/13 (15.4%) |
| Cohort 2: DC-806 + Digoxin + Rosuvastatin (From Day 8) | 0/13 (0%) | 0/13 (0%) | 1/13 (7.7%) |
| Cohort 2: Overall [(DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)] | 0/14 (0%) | 0/14 (0%) | 5/14 (35.7%) |
| Event | Cohort 1: Midazolam + Repaglinide (Days 1 to 3) | Cohort 1: DC-806 (Days 4 to 6) | Cohort 1: DC-806 + Midazolam + Repaglinide (From Day 7) | Cohort 1: Overall [(DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate)] | Cohort 2: Digoxin + Rosuvastatin (Days 1 to 4) | Cohort 2: DC-806 (Days 5 to 7) | Cohort 2: DC-806 + Digoxin + Rosuvastatin (From Day 8) | Cohort 2: Overall [(DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate)] |
|---|---|---|---|---|---|---|---|---|
| DysgeusiaNervous system disorders | 0/14 | 2/14 | 0/14 | 2/14 | 0/14 | 2/13 | 1/13 | 3/14 |
| DizzinessNervous system disorders | 0/14 | 0/14 | 2/14 | 2/14 | 0/14 | 0/13 | 0/13 | 0/14 |
| Upper respiratory tract infectionInfections and infestations | 0/14 | 0/14 | 0/14 | 0/14 | 0/14 | 1/13 | 1/13 | 2/14 |
| DiarrhoeaGastrointestinal disorders | 0/14 | 0/14 | 1/14 | 1/14 | 0/14 | 0/13 | 0/13 | 0/14 |
| NauseaGastrointestinal disorders | 0/14 | 0/14 | 1/14 | 1/14 | 0/14 | 0/13 | 0/13 | 0/14 |
| VomitingGastrointestinal disorders | 0/14 | 0/14 | 1/14 | 1/14 | 0/14 | 0/13 | 0/13 | 0/14 |
| HeadacheNervous system disorders | 0/14 | 0/14 | 0/14 | 0/14 | 1/14 | 0/13 | 0/13 | 1/14 |
| SomnolenceNervous system disorders | 0/14 | 0/14 | 0/14 | 0/14 | 1/14 | 0/13 | 0/13 | 1/14 |
| SinusitisInfections and infestations | 0/14 | 0/14 | 0/14 | 0/14 | 1/14 | 0/13 | 0/13 | 1/14 |
All enrolled participants.
| Age, Continuous(years) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) | Total |
|---|---|---|---|
| Mean | 31.9 ± 9.46 | 35.8 ± 11.57 | 33.8 ± 10.56 |
| Sex: Female, Male(Participants) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) | Total |
|---|---|---|---|
| Female | 0 | 1 | 1 |
| Male | 14 | 13 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 10 |
| Not Hispanic or Latino | 9 | 9 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 13 | 12 | 25 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1: DC-806 / Midazolam (CYP3A4 Substrate) + Repaglinide (CYP2C8 Substrate) | Cohort 2: DC-806 / Digoxin (P-gp Substrate) + Rosuvastatin (BCRP/OATP1B1 Substrate) | Total |
|---|---|---|---|
| United States | 14 | 14 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2023 to primary completion in Nov 2023, 1 month.
Results were first posted in Oct 2026, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DC-806
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company →